	US 12,202,899 B2
	Anti-human PD-L1 antibodies and their uses
Cheng-Chou Yu, Taipei (TW); Shih-Rang Yang, Taipei (TW); Tsung-Han Hsieh, Taipei (TW); Mei-Chi Chan, Taipei (TW); Shu-Ping Yeh, Taipei (TW); Chuan-Lung Hsu, Taipei (TW); Ling-Yueh Hu, Taipei (TW); and Chih-Lun Hsiao, Taipei (TW)
Assigned to Development Center for Biotechnology, Taipei (TW)
Appl. No. 17/256,999
Filed by Development Center for Biotechnology, Taipei (TW)
PCT Filed Jul. 14, 2019, PCT No. PCT/US2019/041747 § 371(c)(1), (2) Date Dec. 29, 2020, PCT Pub. No. WO2020/018395, PCT Pub. Date Jan. 23, 2020.
Claims priority of provisional application 62/698,096, filed on Jul. 14, 2018.
Prior Publication US 2021/0139592 A1, May 13, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01)

CPC C07K 16/2827 (2013.01) [A61K 47/6801 (2017.08); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01)]

15 Claims

1. An anti-PD-L1 antibody, or an antigen-binding fragment thereof, comprising:

a heavy-chain variable region comprising three heavy-chain complementarity-determining regions, HCDR1, HCDR2, and HCDR3, with the sequences of SEQ ID NOs: 2-4, or 6-8, or 10-12, or 14-16, or 18-20; and

a light-chain variable region comprising three light-chain complementarity-determining regions, LCDR1, LCDR2, and LCDR3, with the sequences of SEQ ID NOs: 22-24, or 26-28, or 30-32, or 34-36, or 38-40.